1Sadiq HF, Mantych G, Benawra RS, et al. Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial[J]. J Perinatol,2003, 23(2):98-103.
2Jirapaet KS, Kiatchuskul P, Kolatat T, et al. Comparison of high-frequency flow interruption ventilation and hyperventilation in persistent pulmonary hypertension of the newborn[J]. Respir Care. 2001,46(6):586-94.
3Perkin RM, Levin DL, Clark R. Serum salicylate levels and right-to-left ductus shunts in newborn infants with persistent pulmonary hypertension[J]. J.Pediatr. 1980,96:721-726.
4Daffa SH, Milaat WA. Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the newborn[J]. Saudi Med J. 2002, 23(10):1266-9.
5Andrews AF, Roloff DN, Bartlett RH. Use of extracorporeal membrane oxygenation in persistent pulmonary hypertension of the newborn[J]. Clin Perinatol. 1984, 11:729-735.
6Walton JP, Hendricks-Munoz K. Profile and stability of sensorineural hearing loss in persistent pulmonary hypertension of the newborn[J]. J Speech Hear Res. 1991, 34:1362-1370.
7Wedgwood S, Black SM. Role of reactive oxygen species in vascular remodeling associated with pulmonary hypertension[J]. Antioxid Redox Signal[J]. 2003,5(6): 759-69.
8Steinhorn RH, Millard SL, Morin FC. Persistent pulmonary hypertension of the newborn. Role of nitric oxide and endothelin in pathophysiology and treatment[J]. Clin Perinatol. 1995, 22:405-428.
9Morrow WR, Haas JE, Benjamin DR. Nonbacterial endocardial thrombosis in neonates: relationship to persistent fetal circulation[J]. J.Pediatr. 1982,100:117-122.
10Kamata S, Kamiyama M, Usui N,et al. Is adrenomedulin involved in the pathophysiology of persistent pulmonary hypertension of the newborn[J]? Pediatr Surg Int. 2004 20(1):24-6. Epub 2003 Dec 23.
5Ru-Jeng Teng, Tzong-Jin Wu. Persisitent pulmonary hypertension of the newborn [ J]. J Formos Med Assoc,2013,112(4) :177-184.
6Lapointe A, Barrington KJ. Pulmonary hypertension and the asphyx- iated newborn [ J ]. J Pediatr, 2011,158 ( 8 ) : e19-e24.
7Puthiyachirakkal M, Mhanna MJ. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn : a clinical review [ J ] . Front Pediatr,2013,1 ( 3 ) : 1-6.
8Garcia-Cardena G, Oh P, Liu J, et al. Targeting of nitric oxide syn- thase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling [J]. Proc Natl Acad Sci USA,1996,93(2) : 6448 -6453.
9Pearson DL, Dawling S, Walsh WF, et al. Neonatal pulmonary hy- pertension. Urea-cycle intyermediates, nitric oxide production, and carbamoyl-phosphate synthetase function [ J]. N Engl J Med,2001, 344(11 ) :1832-1838.
10Hemandez-Diaz S, Van Matter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn [ J ]. Pediatrics, 2007,120(4) :e272-e282.
